University of Wisconsin, Milwaukee
Trial Pipeline
Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water
NCT05736302
Neural Mechanisms of Response Inhibition Training for OCRD
NCT05377125
Attention Bias Modification Training for Social Phobia (ABMSP)
NCT06054386
EMST in Patients Undergoing CRT for HNCA
NCT03916809
Breathing Room Intervention to Achieve Better Lung Health in Older Adults
NCT05330780
Step-Up Intervention for Self-Management of Fatigue in Young Adults Receiving Chemotherapy
NCT03000166
Developing Cognitive Training for Tourette Syndrome
NCT01440023
Response Inhibition Training for Individuals With Trichotillomania
NCT01638975
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
What the Pipeline for University of Wisconsin, Milwaukee Shows
According to the ClinicalTrials.gov registry, University of Wisconsin, Milwaukee is linked to 8 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 50% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 50% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Wisconsin, Milwaukee reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Wisconsin, Milwaukee is Chronic Tic Disorders with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.